BioMarin Pharmaceutical Inc.BMRNNASDAQ
LOADING
|||
Switch Symbol:
R&D Expense Growth Under Pressure
Trending lower, below historical average, modest growth trend.
Left:
||||
Year-over-year research & development expense growth
Latest
-278.16%
↓ 9340% below average
Average (39q)
-2.95%
Historical baseline
Range
High:153.85%
Low:-278.16%
CAGR
+8.9%
Consistent expansion
| Period | Value |
|---|---|
| Q3 2025 | -278.16% |
| Q3 2025 | 153.85% |
| Q2 2025 | 1.62% |
| Q1 2025 | -8.52% |
| Q4 2024 | -6.16% |
| Q3 2024 | 0.61% |
| Q2 2024 | -10.34% |
| Q1 2024 | -0.61% |
| Q4 2023 | 7.81% |
| Q3 2023 | 7.87% |
| Q2 2023 | 3.21% |
| Q1 2023 | -0.52% |
| Q4 2022 | 9.45% |
| Q3 2022 | -0.23% |
| Q2 2022 | -1.65% |
| Q1 2022 | -0.16% |
| Q4 2021 | 2.04% |
| Q3 2021 | -2.01% |
| Q2 2021 | 8.33% |
| Q1 2021 | -5.07% |
| Q4 2020 | 6.54% |
| Q3 2020 | -19.26% |
| Q2 2020 | 28.04% |
| Q1 2020 | -17.68% |
| Q4 2019 | -0.09% |
| Q3 2019 | -6.83% |
| Q2 2019 | 1.12% |
| Q1 2019 | 4.68% |
| Q4 2018 | 8.66% |
| Q3 2018 | -8.07% |
| Q2 2018 | -4.55% |
| Q1 2018 | 9.10% |
| Q4 2017 | 9.41% |
| Q3 2017 | 7.73% |
| Q2 2017 | -1.35% |
| Q1 2017 | -17.26% |
| Q4 2016 | 8.96% |
| Q3 2016 | -3.72% |
| Q2 2016 | 5.19% |
| Q1 2016 | -9.84% |